Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Homology Medicines, Inc. | fixx-ex321_11.htm |
| EX-31.2 - EX-31.2 - Homology Medicines, Inc. | fixx-ex312_10.htm |
| EX-31.1 - EX-31.1 - Homology Medicines, Inc. | fixx-ex311_12.htm |
| EX-23.1 - EX-23.1 - Homology Medicines, Inc. | fixx-ex231_6.htm |
| EX-10.2 - EX-10.2 - Homology Medicines, Inc. | fixx-ex102_943.htm |
| EX-4.4 - EX-4.4 - Homology Medicines, Inc. | fixx-ex44_13.htm |
| 10-K - 10-K - Homology Medicines, Inc. | fixx-10k_20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, W. Bradford Smith, Chief Financial Officer of Homology Medicines, Inc. (the “Company”) hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
|
|
(1) |
The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “Report”) fully complies with the requirements of Sections 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 11, 2021 |
|
By: |
/s/ W. Bradford Smith |
|
|
|
|
W. Bradford Smith |
|
|
|
|
Chief Financial Officer (Principal Financial Officer) |